Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma

Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma

B‐cell activating factor (BAFF) promotes the survival and adhesion of multiple myeloma (MM) cells. Tabalumab (LY2127399) is an anti‐BAFF monoclonal antibody. This phase 1, multicenter, open‐label, nonrandomized, dose‐escalation study evaluated the safety, tolerability, pharmacokinetics, pharmacodyna...

Full description

Bibliographic Details
Main Authors: Iida, Shinsuke, Ogiya, Daisuke, Abe, Yasunobu, Taniwaki, Masafumi, Asou, Hiroya, Maeda, Kaijiro, Uenaka, Kazunori, Nagaoka, Soshi, Ishiki, Tsuyoshi, Conti, Ilaria, Tobinai, Kensei
Format: Online
Language:English
Published: John Wiley and Sons Inc. 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021044/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021044/

Similar Items